In the study population “B”, we ex-vivo evaluated the immunomodulatory effect of IL-10 at different concentrations (1, 5, and 10 ng/ml) on the SARS-CoV-2-specific peripheral blood cells responses in COVID-19 patients and NO COVID-19-VC subjects. The gene discussed is IL10; the disease is COVID-19.